Author

M. O. Mohsen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 6

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Assay:proteomics· 5 Research Focus:host-pathogen & immune response· 4 Organism:mouse· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Organism:E. coli· 1

Frequent Co-Authors

M. F. Bachmann· 6 shared M. Vogel· 6 shared X. Chang· 5 shared A. Zeltins· 3 shared D. E. Speiser· 2 shared G. Resevica· 2 shared I. Balke· 2 shared L. Zha· 2 shared

Activity by Year

2020-2021 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

6 shared papersImmunology

M. F. Bachmann

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

Virus-like particles (VLPs) are efficient tools for boosting mRNA-induced antibodies

A.-C. S. Vogt, L. Jörg, B. Martina, P. S. Krenger, X. Chang, A. Zeltins, M. Vogel, M. O. Mohsen, M. F. Bachmann

This study compares antibody responses from homologous and heterologous prime-boost vaccination strategies using mRNA and VLP-based vaccines against SARS-CoV-2.

bioRxiv · Dec 20, 2021Immunology

Intranasal administration of a VLP-based vaccine against COVID-19 induces neutralizing antibodies against SARS-CoV-2 and Variants of Concerns

D. A. Rothen, P. S. Krenger, A. Nonic, I. Balke, A.-C. Vogt, X. Chang, A. Manenti, F. Vedovi, G. Resevica, S. Walton, A. Zeltins, E. Montomoli, M. Vogel, M. F. Bachmann, M. O. Mohsen

This study evaluates an intranasally administered VLP-based vaccine in a murine model, showing strong systemic and mucosal antibody responses against SARS-CoV-2 and its variants.

bioRxiv · Sep 10, 2021 · PreprintImmunology

Bedside formulation of a personalized multi-neoantigen vaccine against mammary carcinoma

M. O. Mohsen, D. E. Speiser, J. Michaux, H. Pak, B. J. Stevenson, M. Vogel, V. P. Inchakalody, S. de Brot, G. Coukos, S. Dermime, M. Bassani-Sternberg, M. F. Bachmann

This paper develops a personalized multi-neoantigen vaccine using long peptides linked to virus-like particles, showing improved anti-tumor effects in a murine mammary carcinoma model.

bioRxiv · Apr 24, 2021Immunology

SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility

M. Vogel, X. Chang, G. Sousa Augusto, M. O. Mohsen, D. E. Speiser, M. F. Bachmann

This study evaluates how mutations in the SARS-CoV-2 RBD affect ACE2 binding and neutralization by antibodies, finding increased affinity and reduced susceptibility to neutralization.

bioRxiv · Mar 4, 2021 · PreprintImmunology

The impact of size on particle drainage dynamics and antibody response

S. Zinkhan, A. Ogrina, I. Balke, G. Resevica, A. Zeltins, S. de Brot, C. Lipp, X. Chang, L. Zha, M. Vogel, M. F. Bachmann, M. O. Mohsen

This study compares the draining kinetics and immunogenicity of round and rod-shaped VLPs, finding that round VLPs are more effective in antigen presentation and induce stronger immune responses.

bioRxiv · Sep 28, 2020Immunology

Development of a vaccine against the newly emerging COVID-19 virus based on the receptor binding domain displayed on virus-like particles

L. Zha, H. Zhao, M. O. Mohsen, L. Hong, Y. Zhou, Z. Li, H. Chen, X. Liu, X. Chang, J. Zhang, D. Li, K. Wu, M. Vogel, M. F. Bachmann, J. Wang

This study develops a vaccine candidate against SARS-CoV-2 using virus-like particles displaying the receptor binding domain, which induces neutralizing antibodies in mice.

bioRxiv · May 6, 2020Immunology